LabCorp announced a new assay in its therapeutic drug monitoring (TDM) DoseASSURE portfolio. The new Certolizumab Concentration and Anti-Certolizumab Antibody DoseASSURE CTZ assay, helps physicians monitor individual drug response for patients who are on Certolizumab, a biologic drug used to treat certain inflammatory diseases, such as rheumatoid arthritis and Crohn’s disease.
LabCorp’s DoseASSURE portfolio provides quantitative, patient-specific measurement which can guide patient therapy. With the launch of the DoseASSURE CTZ, LabCorp now has the most comprehensive biologics TDM menu in the industry, targeting the largest number of biologic drugs.
“Biologic drugs can be life-changing, but individual patient response to biologics can vary greatly,” said David P. King, LabCorp’s chairman and CEO. “LabCorp’s DoseASSURE portfolio helps to deliver on the promise of precision medicine by enabling more effective and more individualized treatment plans that can improve clinical outcomes at reduced costs.”
Studies demonstrate the use of TDM can improve efficacy and prolong successful response to biologic treatment. Accordingly, appropriate use of TDM can diminish the need for disease-related surgery and hospitalization by reducing the risk of treatment failure.
“Our expanding DoseASSURE portfolio demonstrates our commitment to providing world-class diagnostic and patient management solutions for physicians and patients,” said Marcia Eisenberg, Ph.D., chief scientific officer of LabCorp Diagnostics. “LabCorp adds value because our diagnostics expertise and available clinical decision support tools help clinicians integrate biologic drugs and the associated diagnostics into optimal patient care.”
LabCorp’s TDM DoseASSURE portfolio includes eight assays measuring 10 biologic therapies — including Adalimumab, Infliximab, Infliximab-dyyb, Infliximab-abda, Etanercept, Rituximab, Golimumab, Vedolizumab, Ustekinumab, and Certolizumab.